EU trade ministers met pharmaceutical and medtech industry representatives in Dublin on 22 October 2026, at a strategic dialogue on life sciences hosted by Minister Helen McEntee with Trade Commissioner Maroš Šefčovič. The talks came as US tariffs on patented medicines and most-favoured-nation pricing deals put pressure on Europe's medicines sector.
The dialogue was held on the sidelines of the informal meeting of EU trade ministers, known as FAC (Trade), which Ireland hosted on 22 and 23 October as part of its Presidency of the Council of the European Union. The Department of Foreign Affairs and Trade said it would bring together Commissioner Šefčovič, trade ministers from member states with significant pharmaceutical and medical devices sectors, and industry representatives. The official accounts do not name the countries or companies that took part, do not mention US pricing policy directly and do not report any agreed outcome.
- The meeting: a strategic dialogue on life sciences in Dublin on 22 October 2026, hosted by Minister for Foreign Affairs and Trade Helen McEntee with Commissioner Maroš Šefčovič, trade ministers and industry representatives.
- Participants and outcome: the countries, companies and industry bodies present have not been disclosed, and no joint statement was published.
- US tariffs: a US proclamation of 2 April 2026 sets a 100% tariff on patented medicines, capped at 15% for products of the EU, with a zero rate until 20 January 2029 for companies with most-favoured-nation (MFN) pricing and onshoring agreements.
- Health ministers: EU health ministers asked the European Commission in June 2026 to assess whether US pricing policy is delaying launches or raising prices in Europe.
- Irish exposure: Ireland exported €138.6 billion of medical and pharmaceutical products in 2025, 53.2% of all goods exports, and €111.7 billion of goods to the US.
What happened at the Dublin life sciences dialogue
The life sciences session followed a side event on the EU and Canada trade agreement, CETA, on Thursday 22 October. In its announcement, the Department of Foreign Affairs and Trade said the "overarching objective will be on fostering an open dialogue to support European competitiveness".
Minister McEntee set out the economic case before the meeting. "The life sciences sectors of pharmaceuticals and medtech are essential for the EU's competitiveness and account for almost 10% of European GDP," she said. "I want to bring together EU trade ministers with significant life sciences sectors, the European Commission and industry for a strategic reflection to ensure that a vibrant and resilient life sciences ecosystem in Europe can deliver effectively for European citizens, communities, companies and jobs."
A closing statement from the Irish Presidency on 23 October said the Minister had brought "these key constituents together to foster an open dialogue and support a vibrant and resilient ecosystem". It gave no further detail on what was discussed. The names of the industry representatives, including whether the European pharmaceutical federation EFPIA or the Irish Pharmaceutical Healthcare Association (IPHA) attended, are not disclosed in either statement.
The main ministerial meeting on 23 October ended with a discussion on EU and US trade and investment, which the Presidency described as "the most valuable relationship of its kind worldwide", with two-way trade worth €1.8 trillion a year. "I am glad there was broad consensus in the room that engagement and dialogue offer the best way forward to address the challenges facing both the EU and US," Minister McEntee said afterwards.
How US tariffs and pricing deals reach European medicines
The US policy that hangs over the talks has two linked parts: tariffs on imported medicines and pressure on companies to match the lowest prices paid in other wealthy countries. Proclamation 11020, signed on 2 April 2026 under Section 232 of the Trade Expansion Act, imposes a 100% duty on patented pharmaceuticals and their ingredients.
The same proclamation sets the rate at 15% for products of the European Union, Japan, the Republic of Korea, and Switzerland and Liechtenstein, implementing those countries' existing trade deals. Companies with onshoring plans approved by the US Commerce Department pay 20%, rising to 100% on 2 April 2030. Companies that also have MFN pricing agreements with the US Department of Health and Human Services pay no tariff until 20 January 2029. The tariffs took effect on 31 July 2026 for the companies listed in an annex to the proclamation and on 29 September 2026 for all others.
Several categories are left out. The proclamation says generic medicines "including biosimilar products" will not be subject to the tariffs "at this time", and sets a zero rate for orphan drugs where all approved uses are orphan indications, plasma-derived therapies, cell and gene therapies, antibody drug conjugates and some other groups.
The pricing side runs through company deals. SWI swissinfo.ch reported on 21 October that about 26 pharmaceutical companies have signed confidential MFN agreements with the US government, under which they pledge to align US prices with those in other countries in return for immunity from the tariffs. The report says the deals are not written into law and many expire by 2030. It also notes that the US pharmaceutical lobby PhRMA has sued the US government over GLOBE, a mandatory Medicare pricing pilot.
For Europe, the concern is the knock-on effect. If US prices are tied to prices abroad, companies have a reason to seek higher prices in Europe or to delay launches there. The same SWI report describes European industry groups using the US debate to argue for higher prices at home.
Health ministers have already asked Brussels to measure the impact
The trade discussion builds on work started by health ministers. At a Council meeting in Luxembourg in June 2026, EU health ministers asked Health Commissioner Olivér Várhelyi to analyse how the US MFN policy affects European markets, Euronews reported. The Commission was asked to look at which medicines could be affected, whether launches in Europe will be delayed and whether some companies could withdraw products from the EU market. Euronews also cited a Reuters report, based on GlobalData analysis, that drug launches in EU markets fell by about 35% in the ten months after the May 2025 US executive order on MFN pricing, compared with the previous ten months.
Health ministers returned to the theme in Dublin. At the informal meeting of EU health ministers at Dublin Castle on 30 September and 1 October, chaired by Minister for Health Jennifer Carroll MacNeill, a working lunch discussed international pressures on the pharmaceutical sector. According to Agence Europe, ministers called for more secure and diversified supplies, better data sharing and a coordinating role for the Commission, and several said the response must take account of trade, with closer alignment between health and trade policy. The 22 October dialogue brought that trade side to the table.
Why the talks matter for Irish pharmaceutical exports
Few EU countries have as much at stake. Central Statistics Office figures show that Ireland exported a record €260.3 billion of goods in 2025, of which €138.6 billion, or 53.2%, were medical and pharmaceutical products. Exports to the US rose 52% to €111.7 billion, 42.9% of the total. Accountancy firm BDO noted in May that the Central Bank of Ireland had linked weaker US pharmaceutical exports in 2026 to significant stockpiling in 2025.
The trend has since reversed. In the first six months of 2026, exports to the US fell 65.1% to €26.2 billion and medical and pharmaceutical exports fell 55.0% to €38.8 billion, compared with the same period of 2025. The CSO's August 2026 release, published on 16 October, shows medical and pharmaceutical exports of €6.0 billion in the month, down 6.7% on August 2025, and exports to the US of €3.8 billion, down 8.6%. Total goods exports for January to August were €138.4 billion, down 23.9%. The CSO figures do not separate the effect of tariffs from the unwinding of 2025 stockpiling.
Companies with MFN and onshoring agreements avoid the tariff, but their deals link US prices to prices paid abroad, which can include Ireland and other EU markets. That is why the European price and launch questions raised by health ministers and the trade questions raised in Dublin are closely linked for Irish sites.
The key figures at a glance
The table brings together the figures from the Irish Presidency, the US proclamation and the CSO. They come from different sources and periods.
| Measure | Figure |
|---|---|
| Life sciences dialogue | Dublin, 22 October 2026; participants not disclosed |
| Pharma and medtech share of EU GDP | Almost 10% (Minister McEntee) |
| EU and US two-way trade | €1.8 trillion a year (Irish Presidency) |
| US general tariff on patented medicines | 100% |
| US tariff on EU patented medicines | 15% |
| Companies with MFN and onshoring agreements | 0% until 20 January 2029 |
| Generics and biosimilars | Not subject to the tariff at this time |
| Irish medical and pharmaceutical exports, 2025 | €138.6 billion (53.2% of goods exports) |
| Irish goods exports to the US, 2025 | €111.7 billion (42.9% of goods exports) |
| Irish exports to the US, January to June 2026 | €26.2 billion, down 65.1% |
| Irish medical and pharmaceutical exports, August 2026 | €6.0 billion, down 6.7% |
Our Ireland pharma exports tracker and Ireland pharma statistics pages follow the CSO series month by month, and the Ireland pharma map shows where the exporting sites are. For earlier coverage, see our reports on Beneluxa and US pricing pressure, what Ireland's EU Presidency means for pharma and the EU push for US tariff relief.
Frequently Asked Questions (FAQ)
Q: What is most-favoured-nation drug pricing?
A: It is a US policy, launched by executive order in May 2025, that pushes drug companies to bring US prices in line with the lowest prices paid in other developed countries. Companies have signed individual agreements with the US government, and those agreements also exempt them from the new pharmaceutical tariffs until 20 January 2029.
Q: Who took part in the Dublin life sciences dialogue?
A: Minister Helen McEntee hosted it with EU Trade Commissioner Maroš Šefčovič, trade ministers from member states with large pharmaceutical and medtech sectors, and industry representatives. The individual countries, companies and industry associations have not been disclosed.
Q: Did the meeting agree any measures?
A: No agreed measures or joint statement have been published. The Irish Presidency described the session as an open dialogue to support a resilient life sciences ecosystem in Europe.
Q: What US tariff applies to medicines made in Ireland?
A: Under Proclamation 11020, patented medicines from the EU face a 15% tariff, instead of the general 100% rate, unless a lower company rate applies. Companies with MFN and onshoring agreements pay nothing until 20 January 2029, and generics and biosimilars are excluded for now.
Q: Why have Irish pharmaceutical exports to the US fallen in 2026?
A: CSO data show exports to the US fell by almost two-thirds in the first half of 2026 after record shipments in 2025, when companies built up stock ahead of the tariffs. The CSO does not split the fall between stockpiling, tariffs and other factors, although the Central Bank has pointed to the unwinding of 2025 stockpiling.
Conclusion and Outlook
The Dublin dialogue was an exchange of views rather than a negotiation, and nothing concrete has been announced from it. It did, however, put trade ministers, the Commission and the life sciences industry in one room at a time when US tariffs and pricing deals are reshaping where medicines are launched and at what price. Minister McEntee will chair the next formal FAC (Trade) meeting in Brussels on 30 November, and EU health ministers are due to hold a formal Council meeting in December. Whether Europe coordinates its response on price and launch delays, as health ministers have asked, will depend in part on the Commission's analysis of the US policy. Priya Life Science will report the next CSO export figures and any EU statement on medicines pricing as they are published.
Sources
- Department of Foreign Affairs and Trade, Minister McEntee to host meeting of trade ministers in Dublin, 22 October 2026
- Irish Presidency of the Council of the EU, Minister McEntee hosts EU trade ministers in Dublin, 23 October 2026
- Irish Presidency of the Council of the EU, Minister Carroll MacNeill chairs Informal Meeting of EU Health Ministers at Dublin Castle, 1 October 2026
- Agence Europe, European ministers seek closer cooperation to counter pressures on global pharmaceutical market, 2 October 2026
- Compilation of Presidential Documents (GovInfo), Proclamation 11020: Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States, 2 April 2026
- Euronews, EU health chief to probe effects of Trump's drug pricing push, 16 June 2026
- SWI swissinfo.ch, Pharma pushes for higher European drug prices, Trump or no Trump, 21 October 2026
- Central Statistics Office, Goods Exports and Imports December 2025, 17 February 2026
- Central Statistics Office, Goods Exports and Imports June 2026, 18 August 2026
- Central Statistics Office, Goods Exports and Imports August 2026, 16 October 2026
- BDO Ireland, CSO stats show value of exports fall back as pharma levels out, 15 May 2026
Cover image: Upper Castle Yard, Dublin Castle, venue of Irish Presidency ministerial meetings. Photo by William Murphy, Wikimedia Commons, licensed under CC BY-SA 2.0, cropped.
